BDX Becton, Dickinson and Company Common Stock
NYSE · Health Care · SEC EDGAR'da Görüntüle ↗ kapat Eki 2, 2026 10-K/10-Q Ağu 6, 2026BDX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
BDX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
| Ex-tarihi | Bölünme | Tür |
|---|---|---|
| 10 Şubat 2026 | 159-for-125 | İleri |
| 01 Nisan 2022 | 41-for-40 | İleri |
| 21 Ağustos 1998 | 2-for-1 | İleri |
| 16 Ağustos 1996 | 2-for-1 | İleri |
| 01 Mart 1993 | 2-for-1 | İleri |
| 03 Mart 1986 | 2-for-1 | İleri |
Becton, Dickinson and Company Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023.
History
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. It later moved its headquarters to New Jersey.
In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick injury. The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.
In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock.
In April 2017, Becton, Dickinson and Company announced it would acquire C. R. Bard. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
In May 2021, BD announced that it would spin off its diabetes care business (https://investors.bd.com/news-events/press-releases/detail/85/bd-announces-completion-of-embecta-corp-spinoff). The spinoff was completed on April 1, 2022, to form Embecta Corporation. Embecta Corporation is a standalone public company focused on diabetes care. The name "embecta" represents the company's commitment to people living with diabetes and its corporate heritage, with the "em-" prefix evoking empathy for people living with diabetes and the empowerment of the new company and the "bect" imbibed from Becton. Becton, Dickinson and Company entered into an agreement with Embecta Corporation to be their sole supplier of cannulas through 2032. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation's cannulas used in their products.
In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.
In 2024, BD announced it would acquire Edwards Lifesciences' critical care unit for $4.2 billion.
Finances
For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson's shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.
Business segments
Currently there are three business segments.
BD Medical
In certain places, BD Medical also offers consulting and analytics related services. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.
BD Life Sciences
Business units include Biosciences and Integrated Diagnostic Solutions.
Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.
In February 2026, BD Life Sciences was spun out and combined with the businesses of Waters Corporation.
BD Interventional
The company's line of plastic conical screwtop test tubes, known as 'Falcon tubes', is popular and the term is sometimes used as a generic term for such tubes.
Environmental and social track record
As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek's 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.
Pfitzer et al. (2013) identify BD's development of a needleless injection system as an example of leading businesses' role in creating shared value.
Health and safety issues
In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
In 2020, C.R. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.
Recalls
2007 Discardit II incident in Poland
In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
2010 Q-Syte Luer and IV Catheter partial recall
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
2021 IV Giving Sets
In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
Lawsuits
In October 2024, BD agreed to settle around 38,000 US lawsuits brought by plaintiffs who claimed they were injured by BD's hernia meshes.
In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.
Viral Orlando delivery driver incident
On September 6, 2026, in Orlando, Florida, a man identified on social media as Eric Smith, reportedly an employee of medical technology company Becton, Dickinson and Company (BD), drew widespread criticism after a confrontation with a food-delivery worker was captured on video and circulated online.
The video gained significant attention after being shared by social-media commentator Tizzyent on Instagram. During the encounter, the man was recorded making racist remarks toward the delivery worker, demanding her name. The footage subsequently went viral, generating calls on social media for BD to investigate the incident and address the alleged conduct of its employee.
Social-media users subsequently identified the man as Eric Smith and linked him to BD.
Incident recap
The incident reportedly occurred around 8:30 p.m. in Orlando, Florida, while a female delivery driver was making a food delivery. According to the driver, a man confronted her for allegedly blocking the road during her delivery, before questioning her immigration status, making remarks about "illegal immigrants," threatening to call ICE, and saying he would follow her.
The driver said she initially apologized and did not provoke the confrontation. Video of the encounter was later shared by Tizzyent on Instagram, where it went viral and drew widespread criticism.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | BDX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 53.45Y ort. ≈31.2 | ≈31.2 | · | · | |
| PEG Ratio (PEG Oranı) | ≈3.2 | · | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | BDX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 9.6%5Y ort. ≈12.1% | ≈12.1% | · | · | |
| FAVÖK Marjı (TTM) | 21.0%5Y ort. ≈23.6% | ≈23.6% | · | · | |
| Vergi Öncesi Kar Marjı (TTM) | 7.2%5Y ort. ≈9.5% | ≈9.5% | · | · | |
| Net Kâr Marjı (TTM) | 4.5%5Y ort. ≈8.7% | ≈8.7% | · | · | |
| ROA (TTM) | 1.8%5Y ort. ≈3.2% | ≈3.2% | · | · | |
| ROE (TTM) | 3.8%5Y ort. ≈7.0% | ≈7.0% | · | · | |
| ROIC | 5.3%5Y ort. ≈5.3% | ≈5.3% | · | · |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | BDX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.65Y ort. ≈0.6 | ≈0.6 | · | · | |
| Cari Oran (MRQ) | 0.95Y ort. ≈1.2 | ≈1.2 | · | · | |
| Quick Ratio (Cari Oran) | 0.45Y ort. ≈0.5 | ≈0.5 | · | · | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.65Y ort. ≈0.6 | ≈0.6 | · | · | |
| Interest Coverage (Faiz Karşılama Oranı) | 4.25Y ort. ≈5.0 | ≈5.0 | · | · |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | BDX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 8.2%5Y ort. ≈6.5% | ≈6.5% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 5.0%5Y ort. ≈4.4% | ≈4.4% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 6.3% | · | · | · | |
| EPS YoY (EPS YB) | -0.68%5Y ort. ≈28.1% | ≈28.1% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | -1.6%5Y ort. ≈24.2% | ≈24.2% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -0.34%5Y ort. ≈5.6% | ≈5.6% | · | · | |
| EPS CAGR 5Y (EPS Bileşik Yıllık Büyüme Oranı 5Y) | 16.5% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -1.9%5Y ort. ≈3.6% | ≈3.6% | · | · | |
| Net Income CAGR 5Y (Net Gelir Bileşik Yıllık Büyüme Oranı 5Y) | 13.9% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | BDX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.45Y ort. ≈0.4 | ≈0.4 | · | · | |
| Inventory Turnover (Stok Devir Hızı) | 3.15Y ort. ≈3.4 | ≈3.4 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 7.25Y ort. ≈7.9 | ≈7.9 | · | · | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$303.3K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Temettüler Temettü verimi, ödeme oranı, temettü geçmişi, 5 Yıllık CAGR
| Ex-tarihi | Miktar | Para Birimi | Temettü Verimi |
|---|---|---|---|
| Eyl 9, 2026 | $1,05 | USD | ≈2.2% |
| Haz 9, 2026 | $1,05 | USD | ≈2.5% |
| Mar 10, 2026 | $1,05 | USD | ≈2.1% |
| Ara 8, 2025 | $0,83 | USD | ≈2.2% |
| Eyl 8, 2025 | $0,82 | USD | ≈2.2% |
| Haz 9, 2025 | $0,82 | USD | ≈2.4% |
| Mar 10, 2025 | $0,82 | USD | ≈1.7% |
| Ara 9, 2024 | $0,82 | USD | ≈1.7% |
| Eyl 9, 2024 | $0,75 | USD | ≈1.6% |
| Haz 10, 2024 | $0,75 | USD | ≈1.6% |
| Mar 7, 2024 | $0,75 | USD | ≈1.6% |
| Ara 7, 2023 | $0,75 | USD | ≈1.6% |
| Eyl 7, 2023 | $0,72 | USD | ≈1.4% |
| Haz 8, 2023 | $0,72 | USD | ≈1.4% |
| Mar 9, 2023 | $0,72 | USD | ≈1.5% |
| Ara 8, 2022 | $0,72 | USD | ≈1.4% |
| Eyl 8, 2022 | $0,68 | USD | ≈1.3% |
| Haz 8, 2022 | $0,68 | USD | ≈1.3% |
| Mar 9, 2022 | $0,67 | USD | ≈1.3% |
| Ara 9, 2021 | $0,67 | USD | ≈1.4% |
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | $3.23 | $3.17 | 1.8% | |
| 31 Mart 2026 | $2.90 | $2.80 | 3.5% | |
| 31 Aralık 2025 | $2.91 | $2.84 | 2.4% | |
| 30 Eylül 2025 | $3.96 | $3.96 | -0.05% | |
| 30 Haziran 2025 | $3.68 | $3.44 | 7.1% | |
| 31 Mart 2025 | $3.35 | $3.31 | 1.1% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B | $6.13B | $6.49B | $5.59B | $4.14B | |
| Gross Profit | · | · | · | · | · | $7.58B | $8.29B | $7.27B | $5.94B | $5.99B | $4.70B | $4.30B | |
| R&D Expense | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B | $770M | $828M | $632M | $550M | |
| SG&A Expense | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B | $2.91B | $3.00B | $2.56B | $2.15B | |
| Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B | $10.57B | $11.05B | $9.21B | $6.84B | |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912M | $1.76B | $1.51B | $1.52B | $1.43B | $1.07B | $1.61B | |
| Interest Expense | $613M | $528M | $452M | $398M | $469M | $528M | $639M | $706M | $521M | $388M | $371M | $135M | |
| Interest Income | $38M | $163M | $49M | $16M | $9M | $7M | $12M | $65M | $76M | $21M | $15M | $46M | |
| Other Non-op | $-123M | $-28M | $-46M | $-117M | $-99M | $23M | $43M | $305M | $-101M | $11M | $21M | $5M | |
| Pretax Income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414M | $1.18B | $1.17B | $976M | $1.07B | $739M | $1.52B | |
| Income Tax | $203M | $300M | $132M | $148M | $88M | $62M | $-57M | $862M | $-124M | $97M | $44M | $337M | |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| EPS (Basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 | $3.43 | $6.13 | |
| EPS (Diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 | |
| Shares (Basic) | 287,648,000 | 289,763,000 | 286,282,000 | 285,005,000 | 289,288,000 | 278,971,000 | 269,943,000 | 258,354,000 | 218,943,000 | 212,702,000 | 202,537,000 | 193,299,000 | |
| Shares (Diluted) | 288,509,000 | 291,009,000 | 288,392,000 | 287,364,000 | 292,089,000 | 282,402,000 | 274,775,000 | 264,621,000 | 223,588,000 | 217,536,000 | 207,509,000 | 197,709,000 | |
| EBITDA | $5.04B | $4.68B | $4.40B | $4.51B | $5.07B | $3.64B | $4.01B | $3.48B | $2.57B | $2.54B | $1.97B | $2.17B |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $567M | $1.72B | $1.42B | $1.01B | $2.28B | $2.83B | $536M | $1.14B | $14.18B | $1.54B | $1.42B | $1.86B | |
| Receivables | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B | $2.40B | $2.35B | $2.32B | $1.74B | $1.62B | $1.62B | $1.19B | |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B | $2.74B | $2.58B | $2.45B | $1.82B | $1.72B | $1.96B | $1.50B | |
| Other Current Assets | $1.38B | $1.29B | $1.38B | $1.56B | $1.05B | $891M | $1.12B | $1.25B | $871M | $480M | $563M | $698M | |
| Current Assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B | $6.66B | $7.41B | $18.63B | $6.37B | $5.66B | $6.13B | |
| PP&E (Net) | $6.38B | $6.82B | $6.56B | $6.01B | $6.00B | $5.92B | $5.66B | $5.38B | $4.64B | $3.90B | $4.06B | $3.60B | |
| PP&E (Gross) | $13.66B | $14.38B | $13.58B | $12.41B | $12.09B | $11.92B | $11.13B | $10.48B | $9.39B | $8.42B | $8.28B | $7.76B | |
| Accum. Depreciation | $7.27B | $7.56B | $7.02B | $6.40B | $6.09B | $6.00B | $5.47B | $5.11B | $4.75B | $4.52B | $4.22B | $4.16B | |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B | $23.60B | $23.38B | $23.60B | $7.56B | $7.42B | $7.54B | $1.09B | |
| Intangibles | $9.23B | $10.87B | $10.90B | $12.26B | $12.73B | $13.77B | · | · | · | · | · | · | |
| Other Non-current Assets | $2.38B | $2.62B | $2.08B | $1.85B | $1.95B | $1.69B | $1.09B | $1.08B | $1.01B | $824M | $717M | $488M | |
| Total Assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.38B | |
| Accounts Payable | $6.11B | $1.90B | $1.64B | $1.70B | $1.74B | $1.35B | $1.09B | $1.11B | $797M | $665M | $631M | $401M | |
| Accrued Liabilities | $3.10B | $3.48B | $2.60B | $2.60B | $2.87B | $2.64B | $2.13B | $2.25B | $1.39B | $1.57B | $1.62B | $1.05B | |
| Current Liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B | $5.66B | $7.22B | $3.34B | $4.40B | $4.38B | $2.23B | |
| Capital Leases | $704M | $667M | $414M | $384M | $344M | $336M | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | $1.95B | $130M | |
| Other Non-current Liabilities | $2.63B | $3.56B | $4.58B | $5.05B | $5.21B | $5.75B | $5.68B | $5.74B | $1.61B | $1.68B | $2.43B | $383M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $12.12B | $3.77B | |
| Total Debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B | $18.08B | $18.89B | $18.67B | $10.55B | $12.12B | $3.77B | |
| Common Stock | $371M | $371M | $371M | $365M | $365M | $365M | $347M | $347M | $347M | $333M | $333M | $333M | |
| Retained Earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B | $12.79B | $12.91B | $12.60B | $13.11B | $12.73B | $12.31B | $12.11B | |
| Treasury Stock | $9.81B | $8.81B | $8.30B | $8.33B | $7.72B | $6.14B | $6.19B | $6.24B | $8.43B | $8.21B | $8.24B | $8.60B | |
| AOCI | $-1.90B | $-1.73B | $-1.55B | $-1.49B | $-2.09B | $-2.55B | $-2.28B | $-1.91B | $-1.72B | $-1.93B | $-1.74B | $-1.00B | |
| Stockholders' Equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.77B | $21.08B | $20.99B | $12.95B | $7.63B | $7.16B | $5.05B | |
| Liabilities + Equity | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.45B |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B | $891M | $562M | |
| Stock-based Comp | $258M | $247M | $259M | $233M | $229M | $236M | $261M | $322M | $174M | $196M | $166M | $113M | |
| Deferred Tax | $-474M | $-211M | $-622M | $-129M | $-280M | $-285M | $-633M | $-262M | $-74M | $-519M | $-274M | $-94M | |
| Amort. of Intangibles | $1.59B | $1.47B | $1.47B | $1.43B | $1.40B | $1.38B | $1.50B | $1.25B | $553M | $552M | $346M | $84M | |
| Restructuring | $275M | $387M | $239M | $123M | $44M | $84M | · | · | $85M | $526M | $271M | · | |
| Other Non-cash | $-494M | $-183M | $-419M | $-1.64B | $333M | $553M | $216M | $516M | $262M | $792M | $252M | $-20M | |
| Operating Cash Flow | $3.43B | $3.84B | $2.99B | $2.47B | $4.13B | $2.94B | $3.33B | $2.87B | $2.55B | $2.56B | $1.73B | $1.75B | |
| CapEx | $760M | $725M | $874M | $973M | $1.19B | $769M | $957M | $895M | $727M | $693M | $596M | $592M | |
| Investing Cash Flow | $-818M | $-5.51B | $-716M | · | $-1.88B | $-1.23B | $-741M | $-15.73B | $-883M | $-669M | $-8.32B | $-948M | |
| Debt Issued | $0 | $4.52B | $1.66B | $497M | $4.87B | $3.39B | $2.22B | $5.09B | $11.46B | $0 | $6.16B | $0 | |
| Net Debt Issued | $-1.79B | $3.38B | $-493M | $-308M | $-243M | $-1.27B | $-2.52B | $1.09B | $7.48B | $-752M | $6.16B | · | |
| Stock Repurchased | $1.00B | $500M | $0 | $500M | $1.75B | $0 | $0 | $0 | $220M | $0 | $0 | $400M | |
| Net Stock Activity | $-1.00B | $-500M | $0 | $-500M | $-1.75B | · | $0 | $0 | $-220M | $0 | $0 | $-400M | |
| Dividends Paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M | |
| Financing Cash Flow | $-3.62B | $2.09B | $-1.96B | · | $-3.31B | $22M | $-3.22B | $-58M | $10.98B | $-1.76B | $6.19B | $-807M | |
| Net Change in Cash | $-1.00B | $375M | $322M | $-1.23B | $-525M | $2.33B | $-646M | $-12.94B | $12.64B | $117M | $-436M | $-29M | |
| Taxes Paid | $599M | $653M | $629M | $532M | $671M | $523M | $536M | $235M | $265M | $218M | $240M | $330M | |
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B | $2.73B | $2.37B | $1.97B | $1.82B | $1.87B | $1.13B | $1.15B | |
| Levered FCF | $2.12B | $2.67B | $1.70B | $1.13B | $2.98B | $2.26B | $1.70B | $1.78B | $1.24B | $1.51B | $785M | $1.05B |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 44.3% | 47.9% | 45.4% | 49.1% | 48.0% | 45.7% | · | |
| Operating Margin | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% | 8.7% | 10.2% | 9.4% | 12.2% | 11.5% | 10.4% | 19.0% | |
| Net Margin | 7.7% | 8.5% | 7.7% | 9.4% | 10.3% | 5.1% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | |
| Pretax Margin | 8.6% | 9.9% | 8.6% | 9.4% | 11.1% | 5.8% | 6.8% | 7.3% | 8.1% | 8.6% | 7.2% | 18.0% | |
| EBITDA Margin | 23.1% | 23.2% | 22.7% | 23.9% | 25.1% | 21.2% | 23.2% | 21.7% | 21.2% | 20.4% | 19.1% | 25.7% | |
| ROA | 3.0% | 3.1% | 2.8% | 3.3% | 3.9% | 1.7% | 2.3% | 0.68% | 3.5% | 3.8% | 3.5% | 9.6% | |
| ROE | 6.5% | 6.6% | 5.8% | 7.3% | 8.8% | 3.9% | 5.9% | 1.8% | 10.7% | 13.2% | 11.4% | 23.5% | |
| ROIC | 5.3% | 4.7% | 4.8% | 5.3% | 6.4% | 3.2% | 4.7% | 1.0% | 5.3% | 7.1% | 5.2% | 14.2% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 | 1.5 | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | |
| Quick Ratio | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 | 0.9 | 0.5 | 0.5 | 4.8 | 0.7 | 0.7 | 1.4 | |
| Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.7 | 0.7 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.6 | 0.7 | |
| Interest Coverage | 4.2 | 4.5 | 4.7 | 5.7 | 6.0 | 2.8 | 2.8 | 2.1 | 2.8 | 3.7 | 2.9 | 11.9 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.7 | |
| Inventory Turnover | 3.1 | 3.1 | 3.4 | 3.5 | 3.9 | 3.6 | 3.6 | 4.1 | 3.5 | 3.5 | 3.2 | 2.9 | |
| Receivables Turnover | 7.2 | 7.2 | 8.2 | 8.3 | 8.3 | 7.2 | 7.4 | 7.9 | 7.2 | 7.7 | 7.3 | 7.0 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $75.70 | $69.34 | $67.17 | $65.67 | $69.32 | $60.61 | $62.92 | $60.40 | $54.09 | $57.38 | $49.55 | $42.72 | |
| Cash Flow / Share | $11.89 | $13.21 | $10.37 | $8.60 | $15.91 | $12.53 | $12.12 | $10.83 | $11.40 | $11.76 | $8.34 | $8.83 | |
| Dividend Paid / Share | $4.16 | $3.80 | $3.64 | $3.48 | $3.32 | $3.16 | $3.08 | $3.00 | $2.92 | $2.64 | $2.40 | $2.18 | |
| EPS (TTM) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.2% | 4.2% | 2.7% | -1.4% | 19.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.0% | 1.8% | 6.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -0.68% | 18.6% | -16.0% | -14.2% | 152.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -0.34% | -5.1% | 22.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 16.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.6% | 14.9% | -16.6% | -15.0% | 139.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.9% | -6.6% | 19.3% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 13.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Net Income TTM | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| P/E | 25.3 | 32.3 | 41.1 | 29.8 | 27.5 | 65.9 | 49.2 | 333.6 | 32.7 | 30.7 | 30.4 | 14.6 | |
| Earnings Yield | 4.0% | 3.1% | 2.4% | 3.4% | 3.6% | 1.5% | 2.0% | 0.30% | 3.1% | 3.3% | 3.3% | 6.9% | |
| Payout Ratio | 71.3% | 64.5% | 75.1% | 60.8% | 50.1% | 117.4% | 79.8% | 298.1% | 61.6% | 57.6% | 69.8% | 35.5% | |
| Annual Payout | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M |
Gelir Tablosu
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.25B | $5.89B | $4.73B | $4.48B | $5.17B | $5.44B | $4.99B | $5.04B | $4.71B | $5.09B | $4.88B | $4.82B | $4.59B | $4.76B | |
| Cost of Revenue | $2.67B | $2.56B | $2.84B | $3.09B | $2.49B | $2.62B | $2.93B | $2.95B | $2.68B | $2.74B | $2.68B | $3.38B | $2.78B | $2.59B | $2.45B | $2.68B | |
| R&D Expense | $258M | $249M | $306M | $323M | $230M | $232M | $343M | $302M | $299M | $299M | $290M | $281M | $306M | $337M | $313M | $300M | |
| SG&A Expense | $1.26B | $1.21B | $1.39B | $1.37B | $1.16B | $1.12B | $1.32B | $1.25B | $1.20B | $1.19B | $1.21B | $1.14B | $1.19B | $1.21B | $1.19B | $1.18B | |
| Operating Expenses | $4.32B | $4.62B | $4.70B | $5.19B | $3.99B | $4.10B | $4.71B | $4.81B | $4.39B | $4.31B | $4.27B | $4.74B | $4.33B | $4.19B | $4.00B | $4.27B | |
| Operating Income | $663M | $93M | $552M | $698M | $739M | $383M | $453M | $622M | $602M | $734M | $439M | $349M | $549M | $628M | $585M | $489M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $125M | $111M | $113M | $119M | $118M | $102M | $104M | |
| Interest Income | $4M | $9M | $4M | $5M | $4M | $5M | $23M | $55M | $48M | $26M | $34M | $9M | $24M | $10M | $6M | $7M | |
| Other Non-op | $19M | $86M | $-10M | $-36M | $-22M | $-36M | $-16M | $-9M | $-13M | $-2M | $-4M | $-63M | $17M | $8M | $-8M | $-73M | |
| Pretax Income | $554M | $39M | $393M | $509M | $569M | $201M | $306M | $513M | $500M | $633M | $359M | $181M | $471M | $529M | $481M | $320M | |
| Income Tax | $102M | $76M | $11M | $16M | $118M | $43M | $3M | $114M | $13M | $96M | $77M | $28M | $64M | $68M | $-28M | $33M | |
| Net Income | $377M | $-311M | $382M | $493M | $574M | $308M | $303M | $400M | $487M | $537M | $281M | $108M | $407M | $460M | $509M | $288M | |
| EPS (Basic) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.05 | $1.38 | $1.68 | $1.85 | $0.97 | $0.35 | $1.37 | $1.54 | $1.71 | $0.94 | |
| EPS (Diluted) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.04 | $1.37 | $1.68 | $1.85 | $0.96 | $0.35 | $1.36 | $1.53 | $1.70 | $0.92 | |
| Shares (Basic) | 274,788,000 | 280,640,000 | 285,582,000 | · | 287,170,000 | 287,293,000 | 289,505,000 | · | 289,562,000 | 289,518,000 | 290,113,000 | · | 286,317,000 | 284,292,000 | 283,887,000 | · | |
| Shares (Diluted) | 275,158,000 | 280,640,000 | 285,845,000 | · | 287,223,000 | 287,737,000 | 290,389,000 | · | 290,253,000 | 290,344,000 | 291,398,000 | · | 287,944,000 | 285,645,000 | 285,340,000 | · | |
| EBITDA | $1.23B | $656M | $1.17B | · | $882M | $546M | $1.06B | · | $602M | $734M | $1.00B | · | $549M | $628M | $1.15B | · |
Bilanço
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $708M | $813M | $740M | $641M | $735M | $667M | $711M | $1.72B | $4.46B | $2.35B | $1.18B | · | $923M | $1.98B | $612M | · | |
| Receivables | $2.36B | $2.21B | $2.51B | $2.99B | $2.94B | $3.03B | $2.64B | $3.03B | $2.60B | $2.56B | $2.27B | · | $2.41B | $2.41B | $2.28B | · | |
| Inventory | $3.32B | $3.36B | $4.08B | $3.89B | $3.95B | $3.72B | $3.86B | $3.84B | $3.25B | $3.23B | $3.30B | · | $3.59B | $3.66B | $3.60B | · | |
| Other Current Assets | $1.59B | $1.43B | $1.56B | $1.51B | $1.28B | $1.15B | $1.33B | $1.29B | $1.02B | $1.33B | $1.35B | · | $1.28B | $1.44B | $1.54B | · | |
| Current Assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B | $12.21B | $10.34B | $8.16B | · | $8.59B | $9.59B | $8.18B | · | |
| PP&E (Net) | $6.08B | $6.08B | $6.97B | $7.00B | $6.82B | $6.65B | $6.60B | $6.82B | $6.52B | $6.59B | $6.65B | · | $6.47B | $6.36B | $6.25B | · | |
| PP&E (Gross) | $13.60B | $13.55B | $15.24B | $15.11B | $14.85B | $14.41B | $14.16B | $14.38B | $13.92B | $13.93B | $13.90B | · | $13.47B | $13.20B | $12.93B | · | |
| Accum. Depreciation | $7.52B | $7.47B | $8.27B | $8.12B | $8.04B | $7.76B | $7.55B | $7.56B | $7.40B | $7.33B | $7.25B | · | $7.00B | $6.85B | $6.68B | · | |
| Goodwill | $25.94B | $25.95B | $26.62B | $26.61B | $26.60B | $26.44B | $26.33B | $26.46B | $24.55B | $24.57B | $24.60B | $24.52B | $24.58B | $24.78B | $24.76B | $24.62B | |
| Intangibles | $8.02B | $8.35B | $9.01B | $9.39B | $9.77B | $10.12B | $10.47B | $10.87B | $9.86B | $10.21B | $10.57B | · | $11.27B | $11.63B | $11.94B | · | |
| Other Non-current Assets | $2.55B | $2.43B | $3.04B | $3.06B | $2.70B | $2.58B | $2.59B | $2.62B | $2.40B | $2.40B | $2.26B | · | $2.06B | $1.99B | $1.96B | · | |
| Total Assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · | |
| Accounts Payable | $6.11B | $5.93B | $6.14B | $1.97B | $6.35B | $6.09B | $6.35B | $1.90B | $5.41B | $5.31B | $5.52B | · | $5.02B | $5.09B | $5.44B | · | |
| Accrued Liabilities | · | · | · | $3.10B | · | · | · | $3.48B | · | · | · | · | · | · | · | · | |
| Current Liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B | $6.61B | $7.33B | $7.54B | · | $6.88B | $7.30B | $7.62B | · | |
| Capital Leases | · | · | · | $704M | · | · | · | $667M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.39B | $2.46B | $2.81B | $2.93B | $2.83B | $3.00B | $3.42B | $3.56B | $4.07B | $4.30B | $4.41B | · | $4.37B | $4.47B | $4.86B | · | |
| Total Debt | $13.51B | $14.71B | $16.92B | · | $17.53B | $17.67B | $17.44B | · | $18.13B | $15.99B | $14.09B | · | $14.93B | $16.01B | $14.27B | · | |
| Common Stock | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | · | $371M | $365M | $365M | · | |
| Retained Earnings | $17.51B | $17.39B | $16.70B | $16.62B | $16.43B | $16.15B | $16.14B | $16.14B | $16.02B | $15.80B | $15.54B | · | $15.69B | $15.56B | $15.38B | · | |
| Treasury Stock | $12.06B | $11.66B | $10.06B | $9.81B | $9.56B | $9.56B | $9.43B | $8.81B | $8.81B | $8.81B | $8.83B | · | $8.32B | $8.33B | $8.33B | · | |
| AOCI | $-1.65B | $-1.76B | $-1.86B | $-1.90B | $-1.81B | $-1.72B | $-1.68B | $-1.73B | $-1.58B | $-1.53B | $-1.51B | · | $-1.51B | $-1.57B | $-1.56B | $-1.49B | |
| Stockholders' Equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B | $25.87B | $25.65B | $25.33B | · | $25.94B | $25.69B | $25.47B | · | |
| Liabilities + Equity | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · |
Nakit Akışı
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $564M | $563M | $614M | $629M | $575M | $567M | $607M | $586M | $568M | $571M | $561M | $587M | $571M | $563M | $567M | $581M | |
| Stock-based Comp | $55M | $58M | $91M | $55M | $54M | $59M | $90M | $51M | $53M | $60M | $83M | $58M | $56M | $56M | $89M | $49M | |
| Amort. of Intangibles | $365M | $380M | $397M | $398M | $388M | $387M | $395M | $375M | $362M | $366M | $365M | $367M | $367M | $366M | $365M | $366M | |
| Restructuring | $48M | $482M | $75M | $88M | $58M | $63M | $66M | $125M | $95M | $98M | $69M | $119M | $61M | $33M | $26M | $51M | |
| Other Non-cash | · | · | $-845M | · | · | · | $-677M | · | · | · | $82M | · | · | · | $-1.43B | · | |
| Operating Cash Flow | $776M | $671M | $657M | $1.35B | $1.22B | $164M | $693M | $1.18B | $1.30B | $514M | $855M | $1.32B | $1.08B | $185M | $399M | $973M | |
| CapEx | $143M | $125M | $108M | $352M | $174M | $129M | $105M | $296M | $179M | $134M | $116M | $294M | $191M | $181M | $208M | $315M | |
| Investing Cash Flow | · | · | $-183M | $-494M | $-336M | $-192M | $204M | $-3.94B | $-288M | $-1.06B | $-233M | $137M | $-329M | $-233M | $-291M | · | |
| Net Debt Issued | $-2.00B | $-2.00B | $0 | · | · | · | $-875M | · | · | · | $0 | · | · | · | $-528M | · | |
| Stock Repurchased | $0 | $2.00B | $250M | $250M | $0 | $0 | $750M | $0 | $0 | $0 | $500M | $0 | $0 | $0 | $0 | $500M | |
| Net Stock Activity | · | · | $-250M | · | · | · | $-750M | · | · | · | $-500M | · | · | · | · | · | |
| Dividends Paid | $286M | $290M | $299M | $297M | $299M | $298M | $302M | $275M | $275M | $275M | $275M | $265M | $286M | $282M | $281M | $270M | |
| Financing Cash Flow | · | · | $-302M | $-809M | $-841M | $-39M | $-1.93B | $124M | $1.12B | $1.71B | $-862M | $-997M | $-1.79B | $1.37B | $-534M | · | |
| Net Change in Cash | $-152M | $64M | $174M | $53M | $51M | $-66M | $-1.04B | $-2.63B | $2.09B | $1.16B | $-247M | $456M | $-1.04B | $1.32B | $-415M | $-1.60B | |
| Free Cash Flow | · | · | $549M | · | · | · | $588M | · | · | · | $739M | · | · | · | $191M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | $652M | · | · | · | $83M | · |
Kârlılık
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.3% | 2.0% | 10.5% | · | 16.0% | 10.4% | 8.8% | · | 12.1% | 14.5% | 9.3% | · | 11.2% | 13.0% | 12.8% | · | |
| Net Margin | 7.6% | -6.6% | 7.3% | · | 10.4% | 5.8% | 5.9% | · | 9.8% | 10.6% | 6.0% | · | 8.3% | 9.5% | 11.1% | · | |
| Pretax Margin | 11.1% | 0.83% | 7.5% | · | 12.8% | 6.9% | 5.9% | · | 10.0% | 12.6% | 7.6% | · | 9.7% | 11.0% | 10.5% | · | |
| EBITDA Margin | 24.6% | 13.9% | 22.2% | · | 16.0% | 10.4% | 20.5% | · | 12.1% | 14.5% | 21.2% | · | 11.2% | 13.0% | 25.1% | · | |
| ROA | 0.71% | -0.59% | 0.70% | · | 1.0% | 0.57% | 0.57% | · | 0.90% | 0.99% | 0.53% | · | 0.77% | 0.84% | 0.96% | · | |
| ROE | 1.5% | -1.3% | 1.5% | · | 2.2% | 1.2% | 1.2% | · | 1.9% | 2.1% | 1.1% | · | 1.6% | 1.8% | 2.1% | · | |
| ROIC | 1.4% | -0.23% | 1.3% | · | 1.7% | 1.1% | 1.1% | · | 1.3% | 1.5% | 0.87% | · | 1.2% | 1.3% | 1.6% | · |
Likidite ve Solventlik
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | · | 1.1 | 1.1 | 1.1 | · | 1.8 | 1.4 | 1.1 | · | 1.2 | 1.3 | 1.1 | · | |
| Quick Ratio | 0.3 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.4 | · | 1.1 | 0.7 | 0.5 | · | 0.5 | 0.6 | 0.4 | · | |
| Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| LT Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 5.9 | 4.0 | · | 4.6 | 5.3 | 5.7 | · |
Verimlilik
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | |
| Inventory Turnover | 0.7 | 0.7 | 0.7 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | |
| Receivables Turnover | 1.9 | 1.8 | 2.0 | · | 2.0 | 1.9 | 2.1 | · | 2.0 | 2.0 | 2.1 | · | 2.1 | 2.0 | 2.1 | · |
Hisse Başına
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $18.11 | $16.80 | $18.37 | · | $19.18 | $18.32 | $17.80 | · | $17.19 | $17.38 | $16.15 | · | $16.94 | $16.88 | $16.07 | · | |
| Cash Flow / Share | · | · | $2.30 | · | · | · | $2.39 | · | · | · | $2.93 | · | · | · | $1.40 | · | |
| Dividend / Share | $1.05 | $1.05 | $1.05 | · | $1.04 | $1.04 | $1.04 | · | $0.95 | $0.95 | $0.95 | · | $0.91 | $0.91 | $0.91 | · | |
| EPS (TTM) | $3.31 | $3.94 | $6.12 | · | $5.48 | $5.16 | $5.94 | · | $4.84 | $4.52 | $4.20 | · | $5.51 | $5.33 | $5.30 | · |
Değerleme (TTM)
| Metrik | Eğilim | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20.84B | $20.58B | $20.35B | · | $19.81B | $20.07B | $20.64B | · | $19.83B | $19.72B | $19.49B | · | $19.05B | $18.81B | $18.74B | · | |
| Net Income TTM | $941M | $1.14B | $1.76B | · | $1.58B | $1.50B | $1.73B | · | $1.41B | $1.33B | $1.26B | · | $1.66B | $1.62B | $1.61B | · | |
| P/E | 45.7 | 39.9 | 24.9 | · | 24.7 | 34.9 | 30.0 | · | 38.0 | 43.0 | 45.6 | · | 37.7 | 36.5 | 37.7 | · | |
| Earnings Yield | 2.2% | 2.5% | 4.0% | · | 4.0% | 2.9% | 3.3% | · | 2.6% | 2.3% | 2.2% | · | 2.6% | 2.7% | 2.6% | · | |
| Payout Ratio | · | · | 78.3% | · | · | · | 99.7% | · | · | · | 97.9% | · | · | · | 55.2% | · | |
| Annual Payout | $1.17B | $1.19B | $1.19B | · | $1.17B | $1.15B | $1.13B | · | $1.09B | $1.10B | $1.11B | · | $1.12B | $1.10B | $1.09B | · |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Gelir | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Faaliyet Kâr Marjı % | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% |
| Net Gelir | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| Seyreltilmiş Hisse Başı Kâr | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
| Metrik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 |
| Cari Oran | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 |
| Cari Oran | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 |
| Metrik | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B |
Kurumsal Sahipler (13F) 1.555 dosya · $46.7B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 127 (-30 önceki Ç'ye göre) | 141 (-45 önceki Ç'ye göre) | 547 (-18 önceki Ç'ye göre) | 547 (+12 önceki Ç'ye göre) | +9.8M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| VANGUARD GROUP INC | $7.118.281.692 | 36.678.939 | 15,23% | Hisse senetleri |
| BlackRock, Inc. | $3.721.532.551 | 24.592.166 | 7,96% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.722.098.919 | 17.987.834 | 5,83% | Hisse senetleri |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $2.483.123.897 | 8.650.967 | 5,31% | Hisse senetleri |
| STATE STREET CORP | $2.269.959.685 | 15.000.064 | 4,86% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.266.036.001 | 14.974.136 | 4,85% | Hisse senetleri |
| First Eagle Investment Management, LLC | $2.090.674.677 | 13.815.335 | 4,47% | Hisse senetleri |
| Invesco Ltd. | $1.346.608.236 | 8.898.488 | 2,88% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $1.228.361.034 | 8.141.586 | 2,63% | Hisse senetleri |
| FRANKLIN RESOURCES INC | $1.061.064.151 | 7.011.592 | 2,27% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $962.154.023 | 6.357.986 | 2,06% | Hisse senetleri |
| GREENHAVEN ASSOCIATES INC | $859.812.872 | 5.681.708 | 1,84% | Hisse senetleri |
| NORGES BANK | $630.973.916 | 4.169.523 | 1,35% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $556.370.023 | 3.676.534 | 1,19% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $515.287.516 | 3.398.203 | 1,10% | Hisse senetleri |
| MORGAN STANLEY | $502.353.875 | 3.319.590 | 1,08% | Hisse senetleri |
| Clearbridge Investments, LLC | $489.222.504 | 3.232.819 | 1,05% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $474.992.547 | 3.138.786 | 1,02% | Hisse senetleri |
| JPMORGAN CHASE & CO | $440.071.112 | 2.835.692 | 0,94% | Hisse senetleri |
| NORTHERN TRUST CORP | $397.274.543 | 2.625.220 | 0,85% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $385.001.377 | 2.544.118 | 0,82% | Hisse senetleri |
| HARRIS ASSOCIATES L P | $355.771.231 | 2.350.963 | 0,76% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $324.096.377 | 2.141.003 | 0,69% | Hisse senetleri |
| First Pacific Advisors, LP | $319.426.456 | 2.110.794 | 0,68% | Hisse senetleri |
| Legal & General Group Plc | $318.049.508 | 2.101.695 | 0,68% | Hisse senetleri |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $296.900.554 | 1.888.320 | 0,64% | Hisse senetleri |
| Amundi | $274.921.665 | 1.816.703 | 0,59% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $266.177.531 | 1.758.921 | 0,57% | Hisse senetleri |
| Longview Partners (Guernsey) LTD | $255.761.774 | 1.690.093 | 0,55% | Hisse senetleri |
| BRANDES INVESTMENT PARTNERS, LP | $252.955.949 | 1.671.540 | 0,54% | Hisse senetleri |
| Bank of New York Mellon Corp | $247.371.528 | 1.634.649 | 0,53% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $234.270.795 | 1.548.079 | 0,50% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $216.917.330 | 1.433.406 | 0,46% | Hisse senetleri |
| Veritas Asset Management LLP | $210.852.478 | 1.393.329 | 0,45% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $204.226.494 | 1.349.544 | 0,44% | Hisse senetleri |
| BARCLAYS PLC | $191.750.849 | 1.267.104 | 0,41% | Hisse senetleri |
| UBS Group AG | $183.686.019 | 1.213.811 | 0,39% | Hisse senetleri |
| WELLS FARGO & COMPANY/MN | $183.226.555 | 1.210.775 | 0,39% | Hisse senetleri |
| JARISLOWSKY, FRASER Ltd | $175.028.282 | 935.130 | 0,37% | Hisse senetleri |
| COOKE & BIELER LP | $171.990.480 | 1.136.526 | 0,37% | Hisse senetleri |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $167.650.789 | 1.107.849 | 0,36% | Hisse senetleri |
| ProShare Advisors LLC | $162.283.113 | 1.072.379 | 0,35% | Hisse senetleri |
| ENVESTNET ASSET MANAGEMENT INC | $156.784.054 | 1.036.041 | 0,34% | Hisse senetleri |
| RAYMOND JAMES FINANCIAL INC | $152.018.930 | 1.004.552 | 0,33% | Hisse senetleri |
| Focus Partners Wealth | $144.422.511 | 954.318 | 0,31% | Hisse senetleri |
| Findlay Park Partners LLP | $143.945.096 | 951.200 | 0,31% | Hisse senetleri |
| M&G PLC | $134.044.663 | 887.713 | 0,29% | Hisse senetleri |
| FIDUCIARY MANAGEMENT INC /WI/ | $125.873.419 | 831.781 | 0,27% | Hisse senetleri |
| Cullen Capital Management, LLC | $124.804.866 | 824.720 | 0,27% | Hisse senetleri |
| Swiss National Bank | $121.639.357 | 803.802 | 0,26% | Hisse senetleri |
Aktivistler ve %5+ sahipler 5 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Açıklanmayan raporlama kişisi | 08 Eylül 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 01 Eylül 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 25 Ağustos 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 16 Ağustos 2006 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 14 Ağustos 2006 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 83 içeriden öğrenenler · 47 yöneticiler · 27 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Thomas E Polen Jr | Chairman, CEO and President | 13 Ağustos 2026 M | 110.163 | 0 | 2 | $-1.172.631 |
| Vitor Roque | EVP & Chief Financial Officer | 02 Eylül 2026 F | 8.041 | 0 | 0 | $0 |
| Christopher Delorefice | EVP & Chief Financial Officer | 26 Kasım 2025 F | 22.982 | 0 | 0 | $0 |
| Christopher R Reidy | CFO and EVP of Administration | 26 Kasım 2021 A | 31.524 | 0 | 0 | $0 |
| David V Elkins | Executive VP and CFO | 09 Kasım 2012 D | 0 | 0 | 0 | $0 |
| Michael Feld | EVP, Chief Revenue Officer | 28 Eylül 2026 S | 19.644 | 0 | 12 | $-170.822 |
| Roland Goette | EVP and President, EMEA | 11 Ağustos 2026 S | 14.856 | 0 | 1 | $-440.888 |
| Bilal Muhsin | EVP & President Connected Care | 02 Temmuz 2026 F | 41.359 | 0 | 0 | $0 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | 24 Haziran 2026 S | 13.172 | 0 | 5 | $-784.162 |
| Peter Menziuso | EVP and President, BDI | 01 Haziran 2026 A | 14.258 | 0 | 0 | $0 |
| Shana Carol Neal | EVP and Chief People Officer | 06 Nisan 2026 F | 23.966 | 0 | 0 | $0 |
| Lanesha Minnix | EVP and General Counsel | 16 Mart 2026 A | 7.492 | 0 | 0 | $0 |
| Pamela L. Spikner | SVP Controller & CAO | 02 Mart 2026 A | 3.323 | 0 | 0 | $0 |
| David Shan | EVP and Chief ISC Officer | 03 Ocak 2026 F | 8.926 | 0 | 0 | $0 |
| Richard Byrd | EVP & President Interventional | 26 Kasım 2025 F | 13.849 | 0 | 0 | $0 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | 26 Kasım 2025 A | 5.763 | 0 | 0 | $0 |
| Michelle Quinn | EVP and General Counsel | 26 Kasım 2024 A | 6.927 | 0 | 0 | $0 |
| Antoine C Ezell | EVP, President Americas & CMO | 26 Kasım 2024 A | 11.970 | 0 | 0 | $0 |
| Thomas J Spoerel | SVPController & Chief Acct Off | 01 Temmuz 2024 F | 1.928 | 0 | 0 | $0 |
| David Hickey | EVP & President, Life Sciences | 26 Kasım 2023 A | 5.862 | 0 | 0 | $0 |
| Samrat S. Khichi | EVP and General Counsel | 21 Aralık 2022 G | 9.251 | 0 | 0 | $0 |
| Rishi Grover | EVP and Chief ISC Officer | 08 Temmuz 2022 A | 9.439 | 0 | 0 | $0 |
| James Lim | Executive Vice President | 17 Haziran 2022 A | 23.941 | 0 | 0 | $0 |
| Betty D Larson | EVP HR & CHRO | 25 Şubat 2022 M | 5.872 | 0 | 0 | $0 |
| Simon D Campion | EVP and Segment President | 11 Şubat 2022 G | 10.319 | 0 | 0 | $0 |
| Alexandre Conroy | EVP of Integrated Supply Chain | 03 Şubat 2022 M | 21.260 | 0 | 0 | $0 |
| Ribo Alberto Mas | EVP and Pres, Life Sciences | 26 Kasım 2021 A | 11.662 | 0 | 0 | $0 |
| Vincent A Forlenza | Chairman of the Board | 15 Aralık 2020 G | 194.048 | 0 | 0 | $0 |
| Patrick Kaltenbach | EVP & Pres Life Sciences | 26 Kasım 2020 A | 10.340 | 0 | 0 | $0 |
| Charles R Bodner | SVP Corp Fin Chief Acct Office | 06 Eylül 2019 M | 2.037 | 0 | 0 | $0 |
| James W Borzi | EVP & Chief Supply Chain Offcr | 30 Kasım 2018 M | 2.775 | 0 | 0 | $0 |
| William A Tozzi | EVP Pres Interventional | 02 Temmuz 2018 A | 12.830 | 0 | 0 | $0 |
| Nabil Shabshab | Executive Vice President | 11 Mayıs 2018 M | 7.811 | 0 | 0 | $0 |
| John E Gallagher | VP, Corp Finance and Treasurer | 02 Mart 2018 F | 1.975 | 0 | 0 | $0 |
| Linda M Tharby | Executive Vice President | 01 Şubat 2018 M | 13.437 | 0 | 0 | $0 |
| John P Groetelaars | EVP | 02 Ocak 2018 A | 42.508 | 0 | 0 | $0 |
| Ellen R Strahlman | Senior Vice President | 25 Kasım 2017 F | 6.898 | 0 | 0 | $0 |
| Gary M Cohen | Executive Vice President | 11 Eylül 2017 M | 71.770 | 0 | 0 | $0 |
| Stephen Sichak | Executive Vice President | 08 Eylül 2017 M | 7.953 | 0 | 0 | $0 |
| Jeffrey S Sherman | Sr. VP and General Counsel | 25 Mayıs 2017 M | 22.094 | 0 | 0 | $0 |
| Jerome V Hurwitz | Executive Vice President | 06 Mayıs 2016 S | 3.027 | 0 | 0 | $0 |
| William A Kozy | Executive Vice President | 09 Aralık 2015 S | 68.823 | 0 | 0 | $0 |
| Joseph Mercurio | VP and Corporate Controller | 25 Kasım 2014 A | 1.932 | 0 | 0 | $0 |
| Donna M Boles | Senior VP - Human Resources | 17 Mayıs 2013 M | 14.607 | 0 | 0 | $0 |
| Suketu Upadhyay | Senior VP and Controller | 20 Kasım 2012 A | 3.525 | 0 | 0 | $0 |
| William E. Rhodes | Senior Vice President | 20 Kasım 2012 A | 5.972 | 0 | 0 | $0 |
| Edward J Ludwig | Chairman | 20 Mart 2012 G | 95.188 | 0 | 0 | $0 |
| Carrie L Byington | Yönetim kurulu üyesi | 06 Ağustos 2026 A | 5.018 | 0 | 0 | $0 |
| Robert Luther Huffines | Yönetim kurulu üyesi | 06 Ağustos 2026 A | 1.279 | 0 | 0 | $0 |
| Bertram L Scott | Yönetim kurulu üyesi | 18 Şubat 2026 S | 36.763 | 0 | 2 | $-212.345 |
| Christopher Ian Montague Jones | Yönetim kurulu üyesi | 04 Şubat 2026 A | 24.304 | 0 | 0 | $0 |
| Joanne Waldstreicher | Yönetim kurulu üyesi | 27 Ocak 2026 A | 3.391 | 0 | 0 | $0 |
| Jacqueline Wright | Yönetim kurulu üyesi | 27 Ocak 2026 A | 1.279 | 0 | 0 | $0 |
| William M Brown | Yönetim kurulu üyesi | 27 Ocak 2026 A | 4.663 | 0 | 0 | $0 |
| Jeffrey William Henderson | Yönetim kurulu üyesi | 27 Ocak 2026 A | 9.143 | 0 | 0 | $0 |
| Gregory Hayes | Yönetim kurulu üyesi | 27 Ocak 2026 A | 7.159 | 0 | 0 | $0 |
| Andrew R Eckert | Yönetim kurulu üyesi | 27 Ocak 2026 A | 10.423 | 0 | 0 | $0 |
| Timothy M Ring | Yönetim kurulu üyesi | 27 Ocak 2026 A | 59.160 | 0 | 0 | $0 |
| Catherine M Burzik | Yönetim kurulu üyesi | 28 Ocak 2025 A | 14.264 | 0 | 0 | $0 |
| LARSEN MARSHALL O | Yönetim kurulu üyesi | 24 Ocak 2023 A | 28.919 | 0 | 0 | $0 |
| Claire Pomeroy | Yönetim kurulu üyesi | 25 Ocak 2022 A | 9.982 | 0 | 0 | $0 |
| David F Melcher | Yönetim kurulu üyesi | 25 Ocak 2022 A | 6.180 | 0 | 0 | $0 |
| Rebecca W Rimel | Yönetim kurulu üyesi | 08 Eylül 2021 S | 10.618 | 0 | 0 | $0 |
| Gary A Mecklenburg | Yönetim kurulu üyesi | 06 Kasım 2018 A | 25.453 | 0 | 0 | $0 |
| Wilard J Overlock JR | Yönetim kurulu üyesi | 06 Kasım 2018 A | 19.442 | 0 | 0 | $0 |
| James F Orr | Yönetim kurulu üyesi | 24 Ocak 2017 A | 24.257 | 0 | 0 | $0 |
| Basil Anderson | Yönetim kurulu üyesi | 26 Ocak 2016 A | 22.596 | 0 | 0 | $0 |
| Henry P Becton JR | Yönetim kurulu üyesi | 03 Kasım 2015 A | 112.683 | 0 | 0 | $0 |
| Edward Degraan | Yönetim kurulu üyesi | 27 Ocak 2015 A | 22.416 | 0 | 0 | $0 |
| Alfred Sommer | Yönetim kurulu üyesi | 28 Ocak 2014 A | 20.689 | 0 | 0 | $0 |
| Adel Mahmoud | Yönetim kurulu üyesi | 29 Ocak 2013 A | 13.746 | 0 | 0 | $0 |
| Claire Fraser | · | 10 Eylül 2025 S | 22.226 | 0 | 0 | $0 |
| David T Durack | · | 28 Nisan 2011 M | 8.908 | 0 | 0 | $0 |
| Cathy E. Minehan | · | 01 Şubat 2011 A | 8.535 | 0 | 0 | $0 |
| Scott P Bruder | · | 23 Kasım 2010 A | 7.626 | 0 | 0 | $0 |
| Patricia B Shrader | · | 23 Kasım 2010 A | 11.250 | 0 | 0 | $0 |
| John R Considine | · | 24 Kasım 2009 A | 93.438 | 0 | 0 | $0 |
| Alfred John Hanson | · | 25 Kasım 2008 A | 46.146 | 0 | 0 | $0 |
| James E Perrella | · | 31 Ekim 2007 A | 18.520 | 0 | 0 | $0 |
| Margeretha Af Ugglas | · | 31 Ocak 2007 A | 15.920 | 0 | 0 | $0 |
| Jean Marc Dageville | · | 08 Aralık 2004 M | 4.658 | 0 | 0 | $0 |
| Harry N Beaty | · | 03 Mayıs 2004 M | 9.204 | 0 | 0 | $0 |
| OLSON FRANK ALBERT | · | 11 Şubat 2004 A | 21.200 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 145 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| IHI · iShares Trust | 5,24% | 943.719 SH | 11 Eylül 2026 | Günlük |
| CZA · Invesco Exchange-Traded Fund Trust | 2,47% | 23.309 SH | 01 Ekim 2026 | Günlük |
| EQTY · Valued Advisers Trust | 2,14% | 184.537 NS | 31 Temmuz 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2,00% | 12.776 SH | 01 Ekim 2026 | Günlük |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,63% | 79.420 SH | 01 Ekim 2026 | Günlük |
| EPOL · iShares Trust | 1,60% | 69.343 SH | 11 Eylül 2026 | Günlük |
| FXH · First Trust Exchange-Traded AlphaDE… | 1,49% | 94.088 NS | 31 Temmuz 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1,49% | 317.073 NS | 31 Temmuz 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1,01% | 1.134.820 NS | 31 Temmuz 2026 | N-PORT |
| IYH · iShares Trust | 0,81% | 166.236 SH | 11 Eylül 2026 | Günlük |
| RGEF · Tidal Trust III | 0,73% | 35.725 NS | 31 Temmuz 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0,72% | 1.769.988 SH | 19 Ağustos 2026 | Günlük |
| FHLC · FIDELITY COVINGTON TRUST | 0,68% | 135.578 NS | 31 Temmuz 2026 | N-PORT |
| IMCV · iShares Trust | 0,68% | 44.851 SH | 11 Eylül 2026 | Günlük |
| REVS · Columbia ETF Trust I | 0,65% | 13.100 NS | 31 Temmuz 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,64% | 856.811 SH | 19 Ağustos 2026 | Günlük |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,62% | 6.797 NS | 31 Temmuz 2026 | N-PORT |
| IXJ · iShares Trust | 0,62% | 144.713 SH | 11 Eylül 2026 | Günlük |
| CURE · Direxion Shares ETF Trust | 0,52% | 5.422 NS | 31 Temmuz 2026 | N-PORT |
| IWS · iShares Trust | 0,49% | 424.696 SH | 11 Eylül 2026 | Günlük |
| EQIN · Columbia ETF Trust I | 0,48% | 8.836 NS | 31 Temmuz 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0,42% | 148.656 NS | 31 Temmuz 2026 | N-PORT |
| FDLO · FIDELITY COVINGTON TRUST | 0,41% | 35.456 NS | 31 Temmuz 2026 | N-PORT |
| DIVB · iShares Trust | 0,40% | 46.677 SH | 11 Eylül 2026 | Günlük |
| VO · VANGUARD INDEX FUNDS | 0,40% | 5.971.067 SH | 19 Ağustos 2026 | Günlük |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,39% | 17.954.000 | 01 Ekim 2026 | Günlük |
| HUSV · First Trust Exchange-Traded Fund III | 0,38% | 1.706 NS | 31 Temmuz 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0,38% | 31.777 NS | 31 Temmuz 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0,37% | 10.309 SH | 19 Ağustos 2026 | Günlük |
| IWR · iShares Trust | 0,37% | 1.164.966 SH | 11 Eylül 2026 | Günlük |
| VLUE · iShares Trust | 0,36% | 194.404 SH | 11 Eylül 2026 | Günlük |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,35% | 9.750 NS | 31 Temmuz 2026 | N-PORT |
| IMCB · iShares Trust | 0,34% | 32.267 SH | 11 Eylül 2026 | Günlük |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 9.256 NS | 31 Temmuz 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,33% | 18.654 SH | 19 Ağustos 2026 | Günlük |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,30% | 27.935 NS | 31 Temmuz 2026 | N-PORT |
| DGRO · iShares Trust | 0,29% | 717.789 SH | 11 Eylül 2026 | Günlük |
| XOEF · iShares Trust | 0,27% | 347 SH | 11 Eylül 2026 | Günlük |
| DFLV · Dimensional ETF Trust | 0,26% | 104.844 NS | 31 Temmuz 2026 | N-PORT |
| SIZE · iShares Trust | 0,23% | 5.494 SH | 11 Eylül 2026 | Günlük |
| RSP · Invesco Exchange-Traded Fund Trust | 0,20% | 1.087.905 SH | 01 Ekim 2026 | Günlük |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,20% | 10.832 SH | 01 Ekim 2026 | Günlük |
| EUSA · iShares, Inc. | 0,19% | 20.800 SH | 11 Eylül 2026 | Günlük |
| FAB · First Trust Exchange-Traded AlphaDE… | 0,19% | 1.919 NS | 31 Temmuz 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,19% | 5.597.000 | 01 Ekim 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,18% | 171.825 NS | 31 Temmuz 2026 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,18% | 6.482.000 | 01 Ekim 2026 | Günlük |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,18% | 255.000 | 01 Ekim 2026 | Günlük |
| VIG · VANGUARD SPECIALIZED FUNDS | 0,18% | 1.556.657 SH | 19 Ağustos 2026 | Günlük |
| VYM · VANGUARD WHITEHALL FUNDS | 0,18% | 1.134.690 SH | 19 Ağustos 2026 | Günlük |
| PFM · Invesco Exchange-Traded Fund Trust | 0,18% | 7.746 SH | 01 Ekim 2026 | Günlük |
| FEUS · FlexShares Trust | 0,17% | 1.155 NS | 31 Temmuz 2026 | N-PORT |
| IVE · iShares Trust | 0,16% | 457.195 SH | 11 Eylül 2026 | Günlük |
| VTV · VANGUARD INDEX FUNDS | 0,16% | 2.617.912 SH | 19 Ağustos 2026 | Günlük |
| IUSV · iShares Trust | 0,15% | 240.462 SH | 11 Eylül 2026 | Günlük |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,15% | 4.447.000 | 01 Ekim 2026 | Günlük |
| ILCV · iShares Trust | 0,14% | 10.712 SH | 11 Eylül 2026 | Günlük |
| VOOV · VANGUARD ADMIRAL FUNDS | 0,14% | 63.464 SH | 19 Ağustos 2026 | Günlük |
| EMGF · iShares, Inc. | 0,14% | 14.306 SH | 10 Eylül 2026 | Günlük |
| DSI · iShares Trust | 0,14% | 42.114 SH | 11 Eylül 2026 | Günlük |
| IWD · iShares Trust | 0,14% | 632.304 SH | 11 Eylül 2026 | Günlük |
| PRF · Invesco Exchange-Traded Fund Trust | 0,13% | 68.767 SH | 01 Ekim 2026 | Günlük |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,12% | 171.632 SH | 19 Ağustos 2026 | Günlük |
| GLBL · Pacer Funds Trust | 0,12% | 8 NS | 31 Temmuz 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0,12% | 3.749 NS | 31 Temmuz 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,11% | 57.778 SH | 01 Ekim 2026 | Günlük |
| ESG · FlexShares Trust | 0,11% | 840 NS | 31 Temmuz 2026 | N-PORT |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,10% | 9.319 SH | 01 Ekim 2026 | Günlük |
| HDUS · Lattice Strategies Trust | 0,10% | 1.192 NS | 31 Temmuz 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 4.277 SH | 01 Ekim 2026 | Günlük |
| TOPC · iShares Trust | 0,09% | 171 SH | 11 Eylül 2026 | Günlük |
| ACVF · ETF Opportunities Trust | 0,09% | 795 NS | 31 Temmuz 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,08% | 244.485 NS | 31 Temmuz 2026 | N-PORT |
| XVV · iShares Trust | 0,08% | 3.163 SH | 11 Eylül 2026 | Günlük |
| PBP · Invesco Exchange-Traded Fund Trust | 0,08% | 1.621 SH | 01 Ekim 2026 | Günlük |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,07% | 47.593 SH | 01 Ekim 2026 | Günlük |
| IVV · iShares Trust | 0,07% | 3.473.127 SH | 11 Eylül 2026 | Günlük |
| CRBN · iShares Trust | 0,07% | 4.897 SH | 11 Eylül 2026 | Günlük |
| ILCB · iShares Trust | 0,07% | 5.340 SH | 11 Eylül 2026 | Günlük |
| BKLC · BNY Mellon ETF Trust | 0,07% | 24.016 NS | 31 Temmuz 2026 | N-PORT |
| IWB · iShares Trust | 0,07% | 197.581 SH | 11 Eylül 2026 | Günlük |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,07% | 38.024 NS | 31 Temmuz 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0,07% | 13.955 NS | 31 Temmuz 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0,07% | 53.117 NS | 31 Temmuz 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0,07% | 4.662 NS | 31 Temmuz 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0,07% | 321.801 SH | 19 Ağustos 2026 | Günlük |
| ESGV · VANGUARD WORLD FUND | 0,07% | 64.270 SH | 19 Ağustos 2026 | Günlük |
| TOV · EA Series Trust | 0,07% | 1.117 NS | 31 Temmuz 2026 | N-PORT |
| IYY · iShares Trust | 0,07% | 11.794 SH | 11 Eylül 2026 | Günlük |
| DXUV · Dimensional ETF Trust | 0,07% | 2.283 NS | 31 Temmuz 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0,07% | 24 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,07% | 78.106 SH | 11 Eylül 2026 | Günlük |
| USCL · iShares Trust | 0,07% | 10.939 SH | 11 Eylül 2026 | Günlük |
| ITOT · iShares Trust | 0,07% | 359.241 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,07% | 83.341 NS | 31 Temmuz 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,07% | 1.039 NS | 31 Temmuz 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0,06% | 6.630 NS | 31 Temmuz 2026 | N-PORT |
| LRGF · iShares Trust | 0,06% | 13.430 SH | 11 Eylül 2026 | Günlük |
| PHDG · Invesco Actively Managed Exchange-T… | 0,06% | 215 SH | 01 Ekim 2026 | Günlük |
| VOO · VANGUARD INDEX FUNDS | 0,06% | 7.153.108 SH | 19 Ağustos 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | 0,06% | 8.748.767 SH | 19 Ağustos 2026 | Günlük |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,06% | 47.858 SH | 19 Ağustos 2026 | Günlük |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,06% | 47.190 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,06% | 23.933 SH | 19 Ağustos 2026 | Günlük |
| TOK · iShares Trust | 0,06% | 795 SH | 11 Eylül 2026 | Günlük |
| DCOR · Dimensional ETF Trust | 0,06% | 11.787 NS | 31 Temmuz 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0,06% | 1.923 NS | 31 Temmuz 2026 | N-PORT |
| URTH · iShares, Inc. | 0,06% | 25.569 SH | 11 Eylül 2026 | Günlük |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0,05% | 156 NS | 31 Temmuz 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,05% | 21.539 NS | 31 Temmuz 2026 | N-PORT |
| TILT · FlexShares Trust | 0,05% | 6.952 NS | 31 Temmuz 2026 | N-PORT |
| LDEM · iShares Trust | 0,05% | 91 SH | 11 Eylül 2026 | Günlük |
| ACWI · iShares Trust | 0,05% | 94.438 SH | 11 Eylül 2026 | Günlük |
| DFSU · Dimensional ETF Trust | 0,05% | 6.917 NS | 31 Temmuz 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,04% | 11.593 SH | 01 Ekim 2026 | Günlük |
| EMXF · iShares Trust | 0,04% | 384 SH | 11 Eylül 2026 | Günlük |
| ROUS · Lattice Strategies Trust | 0,04% | 1.753 NS | 31 Temmuz 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,04% | 247.589 SH | 19 Ağustos 2026 | Günlük |
| PDN · Invesco Exchange-Traded Fund Trust … | 0,04% | 796 SH | 30 Eylül 2026 | Günlük |
| GLOF · iShares Trust | 0,04% | 380 SH | 11 Eylül 2026 | Günlük |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,04% | 1.792 NS | 31 Temmuz 2026 | N-PORT |
| EMXC · iShares, Inc. | 0,02% | 33.336 SH | 11 Eylül 2026 | Günlük |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,02% | 30.768 SH | 19 Ağustos 2026 | Günlük |
| EEM · iShares, Inc. | 0,02% | 31.606 SH | 10 Eylül 2026 | Günlük |
| IEMG · iShares, Inc. | 0,02% | 152.904 SH | 10 Eylül 2026 | Günlük |
| LGDX · Tidal Trust III | 0,01% | 113 NS | 31 Temmuz 2026 | N-PORT |
| VXUS · VANGUARD STAR FUNDS | 0,01% | 186.147 SH | 19 Ağustos 2026 | Günlük |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0,01% | 125.091 SH | 19 Ağustos 2026 | Günlük |
| VSGX · VANGUARD WORLD FUND | 0,01% | 2.529 SH | 19 Ağustos 2026 | Günlük |
| AQLT · iShares Trust | 0,01% | 158 SH | 10 Eylül 2026 | Günlük |
| PEVC · Pacer Funds Trust | 0,01% | 1 NS | 31 Temmuz 2026 | N-PORT |
| ACWX · iShares Trust | 0,01% | 3.911 SH | 10 Eylül 2026 | Günlük |
| IXUS · iShares Trust | 0,01% | 18.527 SH | 11 Eylül 2026 | Günlük |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Temmuz 2026 | Günlük |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 Temmuz 2026 | Günlük |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | 15 Temmuz 2026 | Günlük |
| VCEB · VANGUARD WORLD FUND | · | · | 30 Temmuz 2026 | Günlük |
BDX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
12 Aylık Fiyat Hedefi
12 analist · 2026-10-01Ortalama hedef $195.67 +10,7%
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.